Pages that link to "Q34249859"

The following pages link to New insights for development of a safe and protective RSV vaccine (Q34249859):

Displaying 44 items.

• Human Metapneumovirus: lessons learned over the first decade (Q26822938) (← links)
• Hsp90 inhibitors exhibit resistance-free antiviral activity against respiratory syncytial virus (Q28486995) (← links)
• Natural killer T cell sensitization during neonatal respiratory syncytial virus infection induces eosinophilic lung disease in re-infected adult mice (Q33751615) (← links)
• Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection (Q33881536) (← links)
• Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model (Q33887642) (← links)
• A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation (Q34401644) (← links)
• Agents that increase AAM differentiation blunt RSV-mediated lung pathology (Q34484085) (← links)
• Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats (Q34506016) (← links)
• Optimization of potent and selective quinazolinediones: inhibitors of respiratory syncytial virus that block RNA-dependent RNA-polymerase complex activity (Q34796481) (← links)
• Novel drugs targeting Toll-like receptors for antiviral therapy (Q34999938) (← links)
• Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection (Q35488618) (← links)
• Contributions of humoral and cellular immunity to vaccine-induced protection in humans. (Q35615024) (← links)
• Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory Tract (Q35690781) (← links)
• Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination (Q35887649) (← links)
• Proteomic contributions to our understanding of vaccine and immune responses (Q36464016) (← links)
• Cell-mediated immune responses to respiratory syncytial virus infection: magnitude, kinetics, and correlates with morbidity and age (Q36977881) (← links)
• Neonatal immunization with respiratory syncytial virus glycoprotein fragment induces protective immunity in the presence of maternal antibodies in mice (Q37086092) (← links)
• Targeting RSV with vaccines and small molecule drugs (Q37328584) (← links)
• A Minimum Epitope Overlap between Infections Strongly Narrows the Emerging T Cell Repertoire. (Q37368692) (← links)
• Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention (Q37841269) (← links)
• Pattern recognition receptors and the innate immune response to viral infection (Q37945230) (← links)
• Pattern recognition receptors for respiratory syncytial virus infection and design of vaccines (Q38018768) (← links)
• Influenza and respiratory syncytial virus (RSV) vaccines for infants: safety, immunogenicity, and efficacy (Q38068065) (← links)
• Respiratory syncytial virus: current progress in vaccine development (Q38079432) (← links)
• Advances in and the potential of vaccines for respiratory syncytial virus (Q38130514) (← links)
• Unmet needs in respiratory diseases : "You can't know where you are going until you know where you have been"--Anonymous (Q38167718) (← links)
• Prevention and prophylaxis of respiratory syncytial virus in pediatric cardiology: a UK perspective. (Q38206841) (← links)
• Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology. (Q38508568) (← links)
• Advances in Antiviral Therapies Targeting Toll-like Receptors (Q38733975) (← links)
• CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells i (Q38919640) (← links)
• Burden of respiratory syncytial virus infection in young children (Q39393694) (← links)
• Respiratory syncytial virus prevention in children with congenital heart disease: who and how? (Q39719279) (← links)
• Selective evolution of Toll-like receptors 3, 7, 8, and 9 in bats (Q40408421) (← links)
• Novel HLA-A2-restricted human metapneumovirus epitopes reduce viral titers in mice and are recognized by human T cells (Q40702974) (← links)
• The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis. (Q40933366) (← links)
• An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization (Q41721418) (← links)
• Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine (Q43625547) (← links)
• The cotton rat (Sigmodon hispidus) as an animal model for respiratory tract infections with human pathogens (Q43788138) (← links)
• RSV 2010: Recent advances in research on respiratory syncytial virus and other pneumoviruses (Q45364295) (← links)
• Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field (Q47553316) (← links)
• Blocking of opioid receptors in experimental formaline-inactivated respiratory syncytial virus (FI-RSV) immunopathogenesis: from beneficial to harmful impacts (Q47562812) (← links)
• Respiratory syncytial virus vaccine development (Q56893551) (← links)
• Vaccine containing G protein fragment and recombinant baculovirus expressing M2 protein induces protective immunity to respiratory syncytial virus (Q61804920) (← links)
• Unveiling Integrated Functional Pathways Leading to Enhanced Respiratory Disease Associated With Inactivated Respiratory Syncytial Viral Vaccine (Q64102227) (← links)